AMOA
MCID: ANP008
MIFTS: 28

Anaplastic Oligoastrocytoma (AMOA)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Anaplastic Oligoastrocytoma

MalaCards integrated aliases for Anaplastic Oligoastrocytoma:

Name: Anaplastic Oligoastrocytoma 53 59 73
Amoa 59

Characteristics:

Orphanet epidemiological data:

59
anaplastic oligoastrocytoma
Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA251663
UMLS via Orphanet 74 C0431108
ICD10 via Orphanet 34 C71.9
UMLS 73 C0431108

Summaries for Anaplastic Oligoastrocytoma

NIH Rare Diseases : 53 Anaplastic oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass.  These brain cells are known as glial cells, which normally protect and support nerve cells in the brain.  Because an oligoastrocytoma is made up of a combination of two cell types, it is known as a mixed glioma.  An oligoastrocytoma is described as anaplastic when the tumor grows quickly and the cancer cells within the tumor have the potential to spread into surrounding brain tissue or to more distant parts of the body.  Oligoastrocytomas usually occur in a part of the brain called the cerebrum and are diagnosed in adults between the ages of 30 and 50.  The exact cause of this condition is unknown.

MalaCards based summary : Anaplastic Oligoastrocytoma, also known as amoa, is related to oligoastrocytoma and medulloblastoma. The drugs Carmustine and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and spinal cord.

Related Diseases for Anaplastic Oligoastrocytoma

Diseases related to Anaplastic Oligoastrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 10.7
2 medulloblastoma 10.0
3 mismatch repair cancer syndrome 10.0
4 leukemia, acute myeloid 10.0
5 leukemia, acute lymphoblastic 10.0
6 cysticercosis 10.0
7 lymphocytic leukemia 10.0
8 astrocytoma 10.0
9 grade iii astrocytoma 10.0
10 oligodendroglioma 10.0
11 paraplegia 10.0
12 myeloid leukemia 10.0
13 anaplastic oligodendroglioma 10.0
14 opsoclonus-myoclonus syndrome 10.0
15 myoclonus 10.0

Graphical network of the top 20 diseases related to Anaplastic Oligoastrocytoma:



Diseases related to Anaplastic Oligoastrocytoma

Symptoms & Phenotypes for Anaplastic Oligoastrocytoma

Drugs & Therapeutics for Anaplastic Oligoastrocytoma

Drugs for Anaplastic Oligoastrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Not Applicable 154-93-8 2578
2
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
3
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
4
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
5 tannic acid Approved Phase 3
6
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
7
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
8
Cyproheptadine Approved Phase 3 129-03-3 2913
9 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
10 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
11 Dermatologic Agents Phase 3,Phase 1,Phase 2
12 Anti-Infective Agents Phase 3,Phase 2,Phase 1
13 Immunologic Factors Phase 3,Phase 2,Phase 1
14 Antiviral Agents Phase 3,Phase 1
15 interferons Phase 3
16 Interferon-alpha Phase 3
17 Serotonin Agents Phase 3
18 Anti-Allergic Agents Phase 3
19 Serotonin Antagonists Phase 3
20 Histamine H1 Antagonists Phase 3
21
Histamine Phosphate Phase 3 51-74-1 65513
22 Antipruritics Phase 3
23 Neurotransmitter Agents Phase 3,Not Applicable
24 Histamine Antagonists Phase 3
25 Gastrointestinal Agents Phase 3,Phase 1,Not Applicable
26
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
27
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
28
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
29
Nintedanib Approved Phase 2 656247-17-5 56843413
30
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
31
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
32
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
33
Vorinostat Approved, Investigational Phase 1, Phase 2,Phase 2 149647-78-9 5311
34
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2,Phase 1 1177-87-3
35
Iodine Approved, Investigational Phase 2 7553-56-2 807
36
Promethazine Approved, Investigational Phase 2 60-87-7 4927
37
Acetaminophen Approved Phase 2 103-90-2 1983
38
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
39
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
40 Antineoplastic Agents, Phytogenic Phase 1, Phase 2
41 Keratolytic Agents Phase 1, Phase 2
42 Podophyllotoxin Phase 1, Phase 2 518-28-5
43 Antimitotic Agents Phase 1, Phase 2
44 Photosensitizing Agents Phase 2,Phase 1
45 Dihematoporphyrin Ether Phase 2,Phase 1
46 tyrosine Phase 2,Phase 1
47 Angiogenesis Inhibitors Phase 2,Phase 1
48 Angiogenesis Modulating Agents Phase 2,Phase 1
49
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
50 Protein Kinase Inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
3 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
4 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
5 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
7 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
8 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
9 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
10 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
11 Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
12 Study of Capecitabine to Treat Recurrent High Grade Gliomas Completed NCT00717197 Phase 2 Capecitabine
13 Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Recruiting NCT02800486 Phase 2 Intra-arterial Cetuximab;Intra-arterial Mannitol
14 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01189266 Phase 1, Phase 2 Vorinostat
15 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
16 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
17 A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Terminated NCT00389090 Phase 2 Temozolomide and O6-Benzylguanine
18 Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) Terminated NCT01110876 Phase 1, Phase 2 Vorinostat;Erlotinib;Temozolomide
19 Phase I/II Cabazitaxel for Recurrent Malignant Glioma Withdrawn NCT01740570 Phase 1, Phase 2 Cabazitaxel
20 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
21 Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor Completed NCT01985256 Phase 1 Toca FC
22 Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor Completed NCT01470794 Phase 1 Toca FC
23 A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma Completed NCT01156584 Phase 1 Toca FC
24 Sorafenib in Newly Diagnosed High Grade Glioma Completed NCT00884416 Phase 1 Sorafenib dose escalation
25 Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors Completed NCT00004080 Phase 1
26 Cellular Immunotherapy Study for Brain Cancer Completed NCT01144247 Phase 1 alloreactive CTL
27 Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Completed NCT01522820 Phase 1 Sirolimus
28 Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Completed NCT01250470 Phase 1 Montanide ISA-51/Survivin Peptide Vaccine
29 Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Completed NCT01234740 Phase 1 bafetinib
30 A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas Completed NCT01172964 Phase 1 flucytosine
31 PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas Completed NCT00612651 Phase 1 Temodar and SCH 66336
32 Ph I SU011248 + Irinotecan in Treatment of Pts w MG Completed NCT00611728 Phase 1 SU011248 & Irinotecan
33 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
34 Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma Completed NCT00979173 Phase 1 AC480
35 A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas Completed NCT00080054 Phase 1 Motexafin Gadolinium Injection
36 Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children Recruiting NCT03043391 Phase 1
37 Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Recruiting NCT01922076 Phase 1 Adavosertib
38 Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma Recruiting NCT03072134 Phase 1
39 Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Recruiting NCT02192359 Phase 1 irinotecan hydrochloride
40 Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Recruiting NCT02255461 Phase 1 palbociclib isethionate
41 A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma Active, not recruiting NCT02026271 Phase 1 veledimex
42 Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma Active, not recruiting NCT01392209 Phase 1
43 Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Active, not recruiting NCT02015819 Phase 1 flucytosine;leucovorin calcium
44 Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma Terminated NCT02168270 Phase 1 temozolomide
45 Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma Terminated NCT01339039 Phase 1 Plerixafor;Plerixafor;Bevacizumab;Plerixafor
46 Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery Terminated NCT02031965 Phase 1 dexamethasone
47 Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I Terminated NCT00671801 Phase 1 Irinotecan;Lenalidomide
48 Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma Withdrawn NCT00734864 Phase 1 enzyme-inducing anti-epileptic drugs;enzyme-inducing anti-epileptic drugs
49 Study About the Validity of MRS-guided Resection on Prognosis High-grade Glioma Gliomas Unknown status NCT02795364 Not Applicable
50 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma Unknown status NCT01637753 Not Applicable Carmustine(BCNU)

Search NIH Clinical Center for Anaplastic Oligoastrocytoma

Genetic Tests for Anaplastic Oligoastrocytoma

Anatomical Context for Anaplastic Oligoastrocytoma

MalaCards organs/tissues related to Anaplastic Oligoastrocytoma:

41
Brain, Bone, Spinal Cord, Myeloid, Bone Marrow

Publications for Anaplastic Oligoastrocytoma

Articles related to Anaplastic Oligoastrocytoma:

(show top 50) (show all 100)
# Title Authors Year
1
Extracranial metastasis of anaplastic oligoastrocytoma. ( 30197798 )
2018
2
Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus. ( 30462564 )
2018
3
Numerical Relationships Between Archaeal and Bacterial amoA Genes Vary by Icelandic Andosol Classes. ( 28707145 )
2018
4
Phylogenetic diversity and distribution of bacterial and archaeal amoA genes in the East China Sea during spring. ( 29143851 )
2018
5
Unifying the global phylogeny and environmental distribution of ammonia-oxidising archaea based on amoA genes. ( 29666365 )
2018
6
Newly designed primer pair revealed dominant and diverse comammox amoA gene in full-scale wastewater treatment plants. ( 30261485 )
2018
7
Nanosilver inhibits nitrification and reduces ammonia-oxidising bacterial but not archaeal amoA gene abundance in estuarine sediments. ( 27376348 )
2017
8
Elevated N2O emission by the rice roots: based on the abundances of narG and bacterial amoA genes. ( 27812967 )
2017
9
A More Comprehensive Community of Ammonia-Oxidizing Archaea (AOA) Revealed by Genomic DNA and RNA Analyses of amoA Gene in Subtropical Acidic Forest Soils. ( 28808742 )
2017
10
AmoA-Targeted Polymerase Chain Reaction Primers for the Specific Detection and Quantification of Comammox Nitrospira in the Environment. ( 28824606 )
2017
11
Hydrography shapes community composition and diversity of amoA-containing Thaumarchaeota in the coastal waters off central Chile. ( 28836743 )
2017
12
Small-scale variation of ammonia oxidisers within intertidal sediments dominated by ammonia-oxidising bacteria Nitrosomonas sp. amoA genes and transcripts. ( 29038459 )
2017
13
Primary spinal cord anaplastic oligoastrocytoma presenting with paraplegia. ( 26851716 )
2016
14
Focal seizure induced by preoperative navigated transcranial magnetic stimulation in a patient with anaplastic oligoastrocytoma. ( 28017645 )
2016
15
A case of medulloblastoma in adult patient affected by anaplastic oligoastrocytoma. ( 27329275 )
2016
16
Underestimation of ammonia-oxidizing bacteria abundance by amplification bias in amoA-targeted qPCR. ( 27166579 )
2016
17
Retraction Note to: Archaeal amoA Genes Outnumber Bacterial amoA Genes in Municipal Wastewater Treatment Plants in Bangkok. ( 27221091 )
2016
18
Effects of high organic load on amoA and nirS gene diversity of an intermittently aerated and fed membrane bioreactor treating landfill leachate. ( 27614578 )
2016
19
Solitary "aggressive" leptomeningeal anaplastic oligoastrocytoma. ( 26318905 )
2015
20
Opsoclonus-myoclonus syndrome in a patient with an anaplastic oligoastrocytoma. ( 25864100 )
2015
21
Anaplastic oligoastrocytoma: is molecular stratification based on 1p/19q status alone appropriate? ( 25555564 )
2015
22
amoA Gene abundances and nitrification potential rates suggest that benthic ammonia-oxidizing bacteria and not Archaea dominate N cycling in the Colne Estuary, United Kingdom. ( 25326303 )
2015
23
Abundance and Activity of 16S rRNA, AmoA and NifH Bacterial Genes During Assisted Phytostabilization of Mine Tailings. ( 25495940 )
2015
24
The abundance of functional genes, cbbL, nifH, amoA and apsA, and bacterial community structure of intertidal soil from Arabian Sea. ( 25862282 )
2015
25
Pesticide Side Effects in an Agricultural Soil Ecosystem as Measured by amoA Expression Quantification and Bacterial Diversity Changes. ( 25938467 )
2015
26
Freshwater Ammonia-Oxidizing Archaea Retain amoA mRNA and 16S rRNA during Ammonia Starvation. ( 25997109 )
2015
27
Corrigendum: Archaeal amoA and ureC genes and their transcriptional activity in the Arctic Ocean. ( 26149188 )
2015
28
Sedimentary archaeal amoA gene abundance reflects historic nutrient level and salinity fluctuations in Qinghai Lake, Tibetan Plateau. ( 26666501 )
2015
29
Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. ( 25523732 )
2014
30
Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child. ( 25489269 )
2014
31
Abundance and diversity based on amoA genes of ammonia-oxidizing archaea and bacteria in ten wastewater treatment systems. ( 24318009 )
2014
32
Transcriptional responses of bacterial amoA gene to dimethyl sulfide inhibition in complex microbial communities. ( 24666625 )
2014
33
Archaeal amoA and ureC genes and their transcriptional activity in the Arctic Ocean. ( 24722490 )
2014
34
Agreement between amoA gene-specific quantitative PCR and fluorescence in situ hybridization in the measurement of ammonia-oxidizing bacteria in activated sludge. ( 25002435 )
2014
35
Diversity of Ammonia Oxidation (amoA) and Nitrogen Fixation (nifH) Genes in Lava Caves of Terceira, Azores, Portugal. ( 26778867 )
2014
36
Archaeal amoA gene diversity points to distinct biogeography of ammonia-oxidizing Crenarchaeota in the ocean. ( 22690844 )
2013
37
Responses of community structure of amoA-encoding archaea and ammonia-oxidizing bacteria in ammonia biofilter with rockwool mixtures to the gradual increases in ammonium and nitrate. ( 23198809 )
2013
38
amoA-encoding archaea in wastewater treatment plants: a review. ( 23306641 )
2013
39
Assessing bacterial diversity in a seawater-processing wastewater treatment plant by 454-pyrosequencing of the 16S rRNA and amoA genes. ( 23574645 )
2013
40
Short-term effect of elevated temperature on the abundance and diversity of bacterial and archaeal amoA genes in Antarctic Soils. ( 23751559 )
2013
41
amoA-encoding archaea and thaumarchaeol in the lakes on the northeastern Qinghai-Tibetan Plateau, China. ( 24273535 )
2013
42
Comparison among amoA primers suited for quantification and diversity analyses of ammonia-oxidizing bacteria in soil. ( 22075625 )
2012
43
amoA-based consensus phylogeny of ammonia-oxidizing archaea and deep sequencing of amoA genes from soils of four different geographic regions. ( 22141924 )
2012
44
Comparative analysis of 16S rRNA and amoA genes from archaea selected with organic and inorganic amendments in enrichment culture. ( 22267662 )
2012
45
The influence of salinity and ammonium levels on amoA mRNA expression of ammonia-oxidizing prokaryotes. ( 22643420 )
2012
46
Analysis and quantification of ammonia-oxidizing bacteria community with amoA gene in sewage treatment plants. ( 22814491 )
2012
47
A novel method for RNA extraction from Andosols using casein and its application to amoA gene expression study in soil. ( 22993110 )
2012
48
High-throughput analysis of ammonia oxidiser community composition via a novel, amoA-based functional gene array. ( 23284709 )
2012
49
Abundance of amoA genes of ammonia-oxidizing archaea and bacteria in activated sludge of full-scale wastewater treatment plants. ( 21185720 )
2011
50
The phylogenetic affiliation of an uncultured population of ammonia-oxidizing bacteria harboring environmental sequences of amoA cluster-3. ( 21715962 )
2011

Variations for Anaplastic Oligoastrocytoma

Expression for Anaplastic Oligoastrocytoma

Search GEO for disease gene expression data for Anaplastic Oligoastrocytoma.

Pathways for Anaplastic Oligoastrocytoma

GO Terms for Anaplastic Oligoastrocytoma

Sources for Anaplastic Oligoastrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....